435 related articles for article (PubMed ID: 25826224)
1. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review.
Kimhofer T; Fye H; Taylor-Robinson S; Thursz M; Holmes E
Br J Cancer; 2015 Mar; 112(7):1141-56. PubMed ID: 25826224
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco-proteogenomics approach.
Chiou SH; Lee KT
Kaohsiung J Med Sci; 2016 Nov; 32(11):535-544. PubMed ID: 27847095
[TBL] [Abstract][Full Text] [Related]
3. Multiple "Omics" data-based biomarker screening for hepatocellular carcinoma diagnosis.
Liu XN; Cui DN; Li YF; Liu YH; Liu G; Liu L
World J Gastroenterol; 2019 Aug; 25(30):4199-4212. PubMed ID: 31435173
[TBL] [Abstract][Full Text] [Related]
4. Advanced mass spectrometry-based multi-omics technologies for exploring the pathogenesis of hepatocellular carcinoma.
Nie W; Yan L; Lee YH; Guha C; Kurland IJ; Lu H
Mass Spectrom Rev; 2016; 35(3):331-49. PubMed ID: 24890331
[TBL] [Abstract][Full Text] [Related]
5. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma.
Wang X; Zhang A; Sun H
Hepatology; 2013 May; 57(5):2072-7. PubMed ID: 23150189
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis of HBV-associated HCC: insights on mechanisms of disease onset and biomarker discovery.
Niu D; Feng H; Chen WN
J Proteomics; 2010 May; 73(7):1283-90. PubMed ID: 20188222
[TBL] [Abstract][Full Text] [Related]
7. Novel proteomic biomarker panel for prediction of aggressive metastatic hepatocellular carcinoma relapse in surgically resectable patients.
Tan GS; Lim KH; Tan HT; Khoo ML; Tan SH; Toh HC; Ching Ming Chung M
J Proteome Res; 2014 Nov; 13(11):4833-46. PubMed ID: 24946162
[TBL] [Abstract][Full Text] [Related]
8. Novel biomarkers in hepatocellular carcinoma.
De Stefano F; Chacon E; Turcios L; Marti F; Gedaly R
Dig Liver Dis; 2018 Nov; 50(11):1115-1123. PubMed ID: 30217732
[TBL] [Abstract][Full Text] [Related]
9. Tissue-based quantitative proteome analysis of human hepatocellular carcinoma using tandem mass tags.
Megger DA; Rosowski K; Ahrens M; Bracht T; Eisenacher M; Schlaak JF; Weber F; Hoffmann AC; Meyer HE; Baba HA; Sitek B
Biomarkers; 2017 Mar; 22(2):113-122. PubMed ID: 27467182
[TBL] [Abstract][Full Text] [Related]
10. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
[TBL] [Abstract][Full Text] [Related]
11. Proteomics for hepatocellular carcinoma marker discovery.
Chignard N; Beretta L
Gastroenterology; 2004 Nov; 127(5 Suppl 1):S120-5. PubMed ID: 15508075
[TBL] [Abstract][Full Text] [Related]
12. Plasma miRNAs as early biomarkers for detecting hepatocellular carcinoma.
Wen Y; Han J; Chen J; Dong J; Xia Y; Liu J; Jiang Y; Dai J; Lu J; Jin G; Han J; Wei Q; Shen H; Sun B; Hu Z
Int J Cancer; 2015 Oct; 137(7):1679-90. PubMed ID: 25845839
[TBL] [Abstract][Full Text] [Related]
13. Proteomic identification of CIB1 as a potential diagnostic factor in hepatocellular carcinoma.
Junrong T; Huancheng Z; Feng H; Yi G; Xiaoqin Y; Zhengmao L; Hong Z; Jianying Z; Yin W; Yuanhang H; Jianlin Z; Longhua S; Guolin H
J Biosci; 2011 Sep; 36(4):659-68. PubMed ID: 21857112
[TBL] [Abstract][Full Text] [Related]
14. A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors.
Reis H; Pütter C; Megger DA; Bracht T; Weber F; Hoffmann AC; Bertram S; Wohlschläger J; Hagemann S; Eisenacher M; Scherag A; Schlaak JF; Canbay A; Meyer HE; Sitek B; Baba HA
Biochim Biophys Acta; 2015 Jun; 1854(6):641-50. PubMed ID: 25448011
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel blood-based HCC-specific diagnostic biomarkers for human hepatocellular carcinoma.
Yin L; He N; Chen C; Zhang N; Lin Y; Xia Q
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1908-1916. PubMed ID: 31072138
[TBL] [Abstract][Full Text] [Related]
16. Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry.
Sun Y; Zang Z; Xu X; Zhang Z; Zhong L; Zan W; Zhao Y; Sun L
Int J Mol Sci; 2010 Mar; 11(4):1423-33. PubMed ID: 20480028
[TBL] [Abstract][Full Text] [Related]
17. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics.
Masuda T; Miyoshi E
Clin Chem Lab Med; 2011 Jun; 49(6):959-66. PubMed ID: 21428856
[TBL] [Abstract][Full Text] [Related]
18. INDEED: Integrated differential expression and differential network analysis of omic data for biomarker discovery.
Zuo Y; Cui Y; Di Poto C; Varghese RS; Yu G; Li R; Ressom HW
Methods; 2016 Dec; 111():12-20. PubMed ID: 27592383
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers for the early diagnosis of hepatocellular carcinoma.
Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
[TBL] [Abstract][Full Text] [Related]
20. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
